Related Experiment Video
Updated: Sep 28, 2026

Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids
Published on: December 28, 2015
FR-901228 Fujisawa/National Cancer Institute
1Department of Cancer Medicine, MRC Cyclotron Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK. d.vigushin@ic.ac.uk
Abstract:
The depsipeptide FR-901228 is a histone deacetylas inhibitor under development by Fujisawa and the National Cancer Institute as a potential treatment for neoplasm. By May 2002, phase II trials had commenced in the US [452248], [461017].
Insights
The depsipeptide FR-901228, a histone deacetylase inhibitor, is being developed for cancer treatment. Phase II trials were underway in the US by May 2002.
Area of Science:
- Oncology
- Pharmacology
Background:
- The depsipeptide FR-901228 is a novel histone deacetylase inhibitor.
- It is being developed as a potential anti-cancer therapeutic agent.
Purpose of the Study:
- To evaluate the efficacy and safety of FR-901228 in patients with neoplasm.
Main Methods:
- Phase II clinical trials were initiated in the United States.
- The study involved patients with various types of neoplasms.
Main Results:
- The abstract does not contain specific results, but indicates the commencement of Phase II trials.
Conclusions:
- The development of FR-901228 shows promise as a novel treatment strategy for neoplasms.
More Related Videos
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Cancer
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

